|Bid||44.01 x 800|
|Ask||47.24 x 1300|
|Day's Range||47.11 - 47.83|
|52 Week Range||30.50 - 50.78|
|Beta (5Y Monthly)||1.09|
|PE Ratio (TTM)||29.85|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||May 05, 2020|
|1y Target Est||N/A|
June 2, 2020 Philips’ IntelliVue Patient Monitors MX750/MX850, IntelliVue 4-Slot Module Rack FMX-4 and IntelliVue Active Displays AD75/AD85 receive FDA Emergency Use.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the company once again has earned a place on the Forbes "Global 2000: The World’s Largest Public Companies" list, moving up 46 spots from 2019. In its new 2020 position, the company now also ranks as one of the top ten global public healthcare companies. The annual list, which has been released for the past 18 years, features a ranking of the biggest, most powerful and most valuable companies in the world. Philips ranked 385 out of the 2,000 publicly traded companies on the full list.
Philips Foundation, with its mission to provide access to quality healthcare for disadvantaged communities through innovation, today announced publication of its 2019 Annual Report. The report outlines a year of substantial progress in providing access to quality healthcare for disadvantaged communities, capturing many of the activities that aim to achieve lasting change in local healthcare systems.
Philips is integrating additional Masimo monitoring technologies into select Philips multi-parameter patient monitors.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its wearable biosensor (Philips Biosensor BX100) to help manage confirmed and suspected COVID-19 patients in the hospital. The next generation wireless wearable biosensor enhances clinical surveillance in the Philips patient deterioration detection solution to help clinicians detect risk so they can intervene earlier and help improve care for patients in lower acuity care areas.
May 19, 2020 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Clinical Trial Accelerator on.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market a wide range of its ultrasound solutions for the management of COVID-19-related lung and cardiac complications. Handheld and portable ultrasound solutions in particular have become valuable tools for clinicians treating COVID-19 patients due to their imaging capabilities, portability and ease of disinfection. As a result of this regulatory clearance, which is an industry first, Philips can provide detailed, practical guidance to support clinicians using its systems and software for patients affected by COVID-19.
Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will convene an Extraordinary General Meeting of Shareholders (EGM) and publish the agenda with explanatory note shortly. The sole purpose of the EGM is submit to Philips’ shareholders the revised proposal, as announced on April 20, 2020, to declare a distribution of EUR 0.85 per common share against the net income for 2019, in shares only. To protect the health and safety of all participants in connection with COVID-19 and considering the temporary legislative measures from the Dutch government, shareholders are invited to submit their voting instructions and follow the meeting via the live webcast only, which will be available on Philips’ website.
May 6, 2020 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the ultimate ultrasound solution.
April 30, 2020 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) announced that today’s Annual General Meeting of Shareholders (2020 AGM) has approved the.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced today that its Emergency Care and Resuscitation (ECR) business is resuming manufacturing and shipping of external defibrillators for the US, following notification from the US Food and Drug Administration (FDA) that the injunction prohibiting those activities has been lifted. This business has been operating under a consent decree with the FDA since November 2017. Under the terms of the consent decree, Philips was required to suspend manufacture and distribution of its defibrillators from specific Philips facilities in the U.S., pending FDA certification via inspection of the facilities’ compliance with Quality System Regulation.
WNEW YORK, NY / ACCESSWIRE / April 20, 2020 / Koninklijke Philips NV (NYSE:PHG) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on April 20, 2020 at 10:00 ...
At Philips, we are focused on our triple duty of care: meeting critical customer needs, safeguarding the health and safety of our employees, and ensuring business continuity. There was increased demand for our professional healthcare products and solutions, with comparable sales and order intake growth for the Connected Care and Diagnosis & Treatment businesses. This resulted in a 2% comparable sales decrease and an Adjusted EBITA margin of 5.9% for the Group.
April 15, 2020 Academic medical center leverages Philips tele-ICU technology to enhance clinician experience and help improve outcomes for ICU patients in Kentucky.
Philips continues to work with its global suppliers to ensure a sufficient and uninterrupted supply of components. Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today provided an update on its plans to double the production of its hospital ventilators by May 2020 and achieve a four-fold increase by the third quarter of 2020.
With the current loss of around 90% of all flights between Europe and Asia, there is a major shortage of freight capacity. At the same time, and precisely because of the crisis surrounding COVID-19, there is a huge requirement to transport medical equipment and other supplies quickly between the US, Europe and China. KLM has now joined forces with Royal Philips (NYSE: PHG; AEX: PHIA) and the Dutch government to create a temporary special cargo airlift between the Netherlands and China.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the U.S. Government and Philips agreed to team up to increase the production of hospital ventilators in its manufacturing sites in the U.S. Philips plans to double the production by May 2020 and achieve a four-fold increase by the third quarter of 2020 for supply to the U.S. and global markets. Such ventilators are critical for the treatment of patients with the new coronavirus disease (COVID-19). Philips will invest several tens of millions in its ventilator manufacturing sites in the U.S.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that the FDA has granted a waiver for the use of readily available consumer monitors at home with the Philips IntelliSite Pathology Solution . Pathologists, who may not be able to work on-site due to the current COVID-19 emergency, can start working from home to review pathological cases and so prevent any delay in critical patient care.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it can help general practitioners and healthcare institutions manage the increased patient flows resulting from the COVID-19 outbreak through a dedicated and scalable telehealth solution that facilitates the use of online screening, follow-up questionnaires and monitoring, and external call center collaborations. It aims to prevent unnecessary visits to general practitioners and hospitals and the remote monitoring of the vast majority of COVID-19 patients that are in quarantine at home.
March 31, 2020 Amsterdam, the Netherlands – In connection with the coronavirus disease (COVID-19) outbreak and related precautionary measures, Royal Philips (NYSE:.
Koninklijke Philips N.V. (“Royal Philips”) (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its issue of EUR 500 million fixed rate notes due 2025 and EUR 500 million fixed rate notes due 2030 (together the “Notes”). The net proceeds of the offering are intended for general company purposes and sustainable innovation expenditures as defined in the ESG framework available on the debt section of Philips Investor Relations website, and will further enhance the company’s liquidity position in view of the possible continued impact of the COVID-19 pandemic on financial markets in 2020. The issue price for the notes due 2025 is 99.550% with a Coupon of 1.375%, resulting in a yield of 1.469%.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Children’s Hospital of Georgia has adopted Philips’ automated early detection and warning solution (IntelliVue GuardianSoftware) for pediatrics. This scalable solution, which could be comprised of a combination of patient monitoring, telehealth, predictive analytics software and services, enables quick identification of signals of clinical patient deterioration and triggers a warning notification to the hospital staff allowing faster response times.
Royal Philips (NYSE: PHG, AEX: PHIA) today provides an update on its EUR 1.5 billion share buyback program for capital reduction purposes, that was announced on January 29, 2019. As of today, 50.3% of the program has been completed through repurchases by an intermediary to allow for purchases in the open market during both open and closed periods. The remainder of the program will be executed through one or more individual forward transactions, to be entered into in the course of 2020, with expected settlement dates in the second half of 2021.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is increasing the production of certain critical care products and solutions to help diagnose and treat patients with the new coronavirus disease (COVID-19). Other Philips products and solutions to help address the preparedness, response and recovery needs of COVID-19 include a range of diagnostic imaging systems (CT, mobile diagnostic X-ray, and ultrasound) to help diagnose and assess respiratory conditions, as well as hospital telehealth solutions to centrally monitor and manage patients in the intensive care unit (Philips eICU program), and telehealth solutions to connect caregivers and patients at home. For example, Philips is ramping up the production of hospital ventilators and plans to double production within the next eight weeks and achieve a four-fold increase by the third quarter of 2020.
March 18, 2020 Amsterdam, the Netherlands – Frans van Houten, CEO of Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today provided an.